Table 4.
Sensitivity of imaging in metastases to soft tissue regions vs bone regions*
| Imaging test | Soft tissue |
Bone |
P | ||
| No. positive/No. of tumor regions | % (95% CI) | No. positive/No. of tumor regions | % (95% CI) | ||
| 18F-FDG PET | 111/143 | 77.6 (70.7 to 84.5) | 59/63 | 93.7 (87.5 to 99.8) | .005† |
| 123I-MIBG SPECT | 54/119 | 45.4 (36.3 to 54.5) | 32/52 | 61.5 (47.9 to 75.2) | .067† |
| CT/MRI | 102/139 | 73.4 (65.9 to 80.8) | 46/60 | 76.7 (65.7 to 87.7) | .724† |
Sensitivities are expressed as the number of positive body regions/the total number of tumor-positive regions, with percentages and 95% CIs. CI = confidence interval; CT/MRI = computed tomography with magnetic resonance imaging; 18F-FDG PET = [18F]-fluorodeoxyglucose positron emission fluorography; 123I-MIBG SPECT = [123I]-metaiodobenzylguanidine single photon emission computed tomography; PGL = paraganglioma; PPGL = pheochromocytoma and paraganglioma.
Fisher exact test, two-sided. Within soft tissue: 18F-FDG vs 123I-MIBG P < .001; 123I-MIBG vs CT/MRI, P < .001 (McNemar test, two-sided). Within bone: 18F-FDG vs 123I-MIBG P < .001; 18F-FDG vs CT/MRI, P = .0129 (McNemar test, two-sided).